Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 50 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXJVWJFUUN3ME2wMlAxODR3ODDuUS=> MYjTRW5ITVJ?
ES4 NUDTZ|Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vXe2lEPTB;MD6wNFA3PTNibl2= NFm5Z5VUSU6JRWK=
ACHN M1X6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD2e41uUUN3ME2wMlAxODh6NzDuUS=> M1H2TXNCVkeHUh?=
KYSE-510 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CybmlEPTB;MD6wNFA6PzVibl2= MXrTRW5ITVJ?
EW-7 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\pe2lEPTB;MD6wNFI2QCCwTR?= NID6[odUSU6JRWK=
BFTC-905 NGOyS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDJTWM2OD1yLkCwOVE2KG6P MVrTRW5ITVJ?
KE-37 M2T2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PzVGlEPTB;MD6wNFU3OSCwTR?= NUP3eVk6W0GQR1XS
SBC-5 NFXEbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjNXnY5UUN3ME2wMlAxPTdibl2= MliyV2FPT0WU
NKM-1 NHXRTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvuTWM2OD1yLkCwO|A6KG6P NIPGN3lUSU6JRWK=
RH-1 NUXwRWpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3aTWM2OD1yLkCwO|E5KG6P MUTTRW5ITVJ?
ALL-PO MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4faNWlEPTB;MD6wNFg{KG6P MlO3V2FPT0WU
QIMR-WIL MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLlTWM2OD1yLkCwPFk1KG6P NF3FW2pUSU6JRWK=
A375 NWPOTYNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH5N49zUUN3ME2wMlAxQTl3IH7N NYPhd49vW0GQR1XS
SIG-M5 NVHqbmhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLpVmhZUUN3ME2wMlAyODRibl2= M3e4eXNCVkeHUh?=
KGN MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMEGwPEBvVQ>? MYDTRW5ITVJ?
EW-13 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH5TWM2OD1yLkCxNVIhdk1? MYDTRW5ITVJ?
NCI-SNU-1 Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S4OmlEPTB;MD6wNVYhdk1? MkPzV2FPT0WU
PSN1 NIrHRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq2TWM2OD1yLkCxOlUhdk1? NECxO5VUSU6JRWK=
HUTU-80 M1TQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDkVnZ{UUN3ME2wMlAyPjZibl2= MXnTRW5ITVJ?
EW-16 M2TMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofDTWM2OD1yLkCyN{BvVQ>? M3[x[XNCVkeHUh?=
786-0 NUP3ZmJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3LN5JiUUN3ME2wMlAzOyCwTR?= NIH6SpNUSU6JRWK=
ES1 NVq5fFdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL3eoVKSzVyPUCuNFI3QCCwTR?= NYrhUGRwW0GQR1XS
RKO NG\GOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG1XlNKSzVyPUCuNFI4QSCwTR?= M{jp[nNCVkeHUh?=
ESS-1 M3X4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMEK4OkBvVQ>? NVjGNo5qW0GQR1XS
SK-UT-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zCT2lEPTB;MD6wNlk4KG6P Ml\ZV2FPT0WU
LB2241-RCC MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DhUmlEPTB;MD6wN|E5KG6P M{O1bnNCVkeHUh?=
CHL-1 NHzDVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:4do9DUUN3ME2wMlA{OjRibl2= MXPTRW5ITVJ?
SW1783 M3ra[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrBTWM2OD1yLkCzN|Yhdk1? M3fteXNCVkeHUh?=
MEL-JUSO M2e5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC4b5RKSzVyPUCuNFM6OSCwTR?= NGnYWXBUSU6JRWK=
HT-29 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DUOWlEPTB;MD6wOFE{KG6P NHv1N5FUSU6JRWK=
SNG-M M{LXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vTWmlEPTB;MD6wOFI2KG6P M{\0ZnNCVkeHUh?=
TE-15 MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO4OWtSUUN3ME2wMlA1PjRibl2= MWXTRW5ITVJ?
HOS NUTqd3ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMES4JI5O MYXTRW5ITVJ?
BB65-RCC NE\CW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMEWxNkBvVQ>? NUPGbGd2W0GQR1XS
HCE-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMEWyPEBvVQ>? MWnTRW5ITVJ?
MHH-ES-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTmUFJsUUN3ME2wMlA2OzFibl2= Ml;lV2FPT0WU
RPMI-7951 NH7LXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjOSnNKSzVyPUCuNFU1OSCwTR?= NVy5SolRW0GQR1XS
IST-SL2 NV6wb49nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjpdZIzUUN3ME2wMlA2QDRibl2= NIrCcWFUSU6JRWK=
CMK MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TYOGlEPTB;MD6wOVg3KG6P MXjTRW5ITVJ?
GR-ST NUPJS|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMEW5OUBvVQ>? M3XufHNCVkeHUh?=
NALM-6 NIjNVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK4TWM2OD1yLkC2NlIhdk1? MkXTV2FPT0WU
RPMI-6666 M4rmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj2RZBKSzVyPUCuNFY2OiCwTR?= MXPTRW5ITVJ?
LC-2-ad NIqzeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;jZoRKSzVyPUCuNFY2OyCwTR?= NYr1O3dmW0GQR1XS
ARH-77 NVnRRlFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;RXlNKSzVyPUCuNFcyOSCwTR?= NIT4TnZUSU6JRWK=
IST-MEL1 NXmwUlh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\ZUoxUUUN3ME2wMlA4OjZibl2= M{DMfnNCVkeHUh?=
SW1710 MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfkZnA6UUN3ME2wMlA4PTFibl2= MXXTRW5ITVJ?
DEL M3PufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fDbmlEPTB;MD6wPFg4KG6P NHmwW41USU6JRWK=
AGS NGX1boRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjBR3lKSzVyPUCuNFkxOiCwTR?= MmLNV2FPT0WU
NCI-H2122 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXHTWM2OD1yLkC5OFYhdk1? NXjNUVNpW0GQR1XS
HSC-4 M{e3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInSNXpKSzVyPUCuNVAzKG6P MWDTRW5ITVJ?
AM-38 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDZTWM2OD1yLkGyNUBvVQ>? MWDTRW5ITVJ?
769-P M2PjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvRTXJKSzVyPUCuNVI{KG6P M4TFS3NCVkeHUh?=
RT-112 MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\KZYhKSzVyPUCuNVI4KG6P MV3TRW5ITVJ?
MCF7 M4HPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\ETWM2OD1yLkGzOkBvVQ>? MXPTRW5ITVJ?
IGROV-1 M3m3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDUTWM2OD1yLkG0OUBvVQ>? M1m4SXNCVkeHUh?=
OCI-AML2 NWq5NY9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjRTWM2OD1yLkG0O{BvVQ>? M2TC[XNCVkeHUh?=
NCI-H1299 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LyRmlEPTB;MD6xOVchdk1? MYLTRW5ITVJ?
A431 Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT6TWM2OD1yLkG4N{BvVQ>? M1LvXHNCVkeHUh?=
SW982 NU\3T|kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfWTWM2OD1yLkKxN{BvVQ>? MkD0V2FPT0WU
BB30-HNC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTLTmlKSzVyPUCuNlMyKG6P NFTPSplUSU6JRWK=
ACN NWnoRXk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XQ[2lEPTB;MD6yOFQhdk1? MnTvV2FPT0WU
647-V NEnMcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qwbmlEPTB;MD6yOFghdk1? M4rBd3NCVkeHUh?=
SK-PN-DW MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fn[2lEPTB;MD6yOlYhdk1? NGrGTmRUSU6JRWK=
LCLC-97TM1 M3Sxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PqNWlEPTB;MD6yOlchdk1? NFTIUmRUSU6JRWK=
LB1047-RCC NVy5eGRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nBc2lEPTB;MD6yOlkhdk1? M33VSHNCVkeHUh?=
A2780 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGW4XotKSzVyPUCuNlchdk1? NF\yUmNUSU6JRWK=
C-33-A M4[2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHDTWM2OD1yLkK3N{BvVQ>? MkSxV2FPT0WU
NCI-H2228 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnpVY5oUUN3ME2wMlMyPCCwTR?= NIjpdG5USU6JRWK=
TE-5 NITUVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvjfFhxUUN3ME2wMlMyPiCwTR?= MofDV2FPT0WU
HC-1 M4HpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwM{K3JI5O NIfObY5USU6JRWK=
SK-MES-1 MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PGR2lEPTB;MD6zNlghdk1? MX7TRW5ITVJ?
NCI-H1355 M2TMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX6eW97UUN3ME2wMlM5OSCwTR?= MXzTRW5ITVJ?
YKG-1 Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXOZ4p{UUN3ME2wMlQyQSCwTR?= NGfRNGpUSU6JRWK=
RS4-11 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi0PZM5UUN3ME2wMlQ{OyCwTR?= NH7scG1USU6JRWK=
Daoy Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwNEW2JI5O M13iW3NCVkeHUh?=
A3-KAW MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\DXpFKSzVyPUCuOVUyKG6P M4Pvb3NCVkeHUh?=
SK-MEL-30 NHLpVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG2bGRYUUN3ME2wMlU2PCCwTR?= NF;CcI1USU6JRWK=
U031 M2P6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLsOXVKSzVyPUCuOVY2KG6P MVXTRW5ITVJ?
SK-LMS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwNUe4JI5O M{TNbHNCVkeHUh?=
ES6 M2PNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrwNIlpUUN3ME2wMlU5PiCwTR?= NVXzXI9zW0GQR1XS
EoL-1-cell NHr2V3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDHTWM2OD1yLk[xOkBvVQ>? M{\QOHNCVkeHUh?=
NCI-H2009 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTS[nFKSzVyPUCuOlE6KG6P M1jEN3NCVkeHUh?=
A4-Fuk NWDhc4o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPiXINKSzVyPUCuOlI3KG6P NW\IeFB5W0GQR1XS
KYSE-270 NHXRVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\keHdVUUN3ME2wMlY{PCCwTR?= NVj4VYxDW0GQR1XS
SK-LU-1 NWnRNFJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwNkW1JI5O M{PNXHNCVkeHUh?=
SW872 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\5NGlEPTB;MD63OlUhdk1? NXfL[WZtW0GQR1XS
ES8 NXi2TXA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfJ[YtKSzVyPUCuO|ghdk1? M4HjUHNCVkeHUh?=
G-402 M1jnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln0TWM2OD1yLke4OEBvVQ>? MWXTRW5ITVJ?
ATN-1 NVznfnNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzZTnZKSzVyPUCuPFA4KG6P MmrwV2FPT0WU
DoTc2-4510 NE[yVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXxbHpKSzVyPUCuPVAyKG6P NEHQTJRUSU6JRWK=
MES-SA NWnnOpNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfoV2RKSzVyPUCuPVA2KG6P M3jsfnNCVkeHUh?=
SF268 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDERYdCUUN3ME2wMlkzPyCwTR?= NULhOWh1W0GQR1XS
SF539 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHVWm02UUN3ME2xMlAzKG6P MVPTRW5ITVJ?
NB69 M1LvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjIS4M1UUN3ME2xMlA2KG6P MV;TRW5ITVJ?
8505C MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W1bmlEPTB;MT6wOkBvVQ>? MV3TRW5ITVJ?
CAL-12T NVzlfWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwMEigcm0> M3zQNHNCVkeHUh?=
BHY MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7E[|dKSzVyPUGuNVQhdk1? M37sS3NCVkeHUh?=
LB647-SCLC MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:0W2lEPTB;MT6xPEBvVQ>? MnjMV2FPT0WU
CAL-62 M{\BcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwMkKgcm0> MWHTRW5ITVJ?
MEG-01 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\Oe2lEPTB;MT6yO{BvVQ>? NGi0dWZUSU6JRWK=
MG-63 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjLWIFKSzVyPUGuN|Mhdk1? NU\yWnpZW0GQR1XS
SW620 NULEd4FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwM{Wgcm0> NUXOO4xmW0GQR1XS
A388 NGTCeGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlOwTWM2OD1zLkO2JI5O MkH4V2FPT0WU
BCPAP MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PtfWlEPTB;MT60OUBvVQ>? NXn2U2pbW0GQR1XS
P30-OHK MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq2dFRKSzVyPUGuOFYhdk1? NVHoZZdFW0GQR1XS
Ca9-22 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fxNWlEPTB;MT61OEBvVQ>? NEHJdGFUSU6JRWK=
VMRC-RCZ M1rYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLFUmh[UUN3ME2xMlU1KG6P MonVV2FPT0WU
LOXIMVI NYfHO4hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPzTWM2OD1zLk[gcm0> NWG3d|dCW0GQR1XS
L-540 NFTjToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnMTWM2OD1zLk[gcm0> MojYV2FPT0WU
NTERA-S-cl-D1 NEX1WmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HlSmlEPTB;MT62OEBvVQ>? Moq3V2FPT0WU
MFH-ino NGrnbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf5WJJKSzVyPUGuOlYhdk1? M3H3O3NCVkeHUh?=
Calu-6 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwN{Ogcm0> NF;l[4NUSU6JRWK=
HEL NVvEPIJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H5TGlEPTB;MT63PUBvVQ>? NWrQdW5CW0GQR1XS
CAL-33 NVTkWVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwOEmgcm0> MYHTRW5ITVJ?
HSC-3 M4rjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfEemdzUUN3ME2xMlkyKG6P NH\CO3NUSU6JRWK=
KU812 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTFwOUGgcm0> NEOxbmJUSU6JRWK=
EB2 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwMEGgcm0> NHzVcJdUSU6JRWK=
SR MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkniTWM2OD1{LkGyJI5O NYi1do9OW0GQR1XS
NCI-H2087 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\3SlJbUUN3ME2yMlE1KG6P NILBfW9USU6JRWK=
H4 NXLXXFZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfXTWM2OD1{LkG4JI5O NVfDWId7W0GQR1XS
EW-1 NX\le2ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPJTWM2OD1{LkKyJI5O NYDZ[|hDW0GQR1XS
MC-IXC NX\UV3VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\D[lRKSzVyPUKuNlYhdk1? MXjTRW5ITVJ?
NCI-H727 M3r6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJwNUGgcm0> M{LEVHNCVkeHUh?=
MRK-nu-1 MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\wTmZIUUN3ME2yMlU4KG6P NGDIUppUSU6JRWK=
COLO-668 NV;Dc4Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;lVIdKSzVyPUKuOlYhdk1? NVPzOYxiW0GQR1XS
CGTH-W-1 M2[5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTsfFRjUUN3ME2yMlczKG6P MV\TRW5ITVJ?
CHP-212 M1Xuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jGZ2lEPTB;Mj63OUBvVQ>? NWH1bndnW0GQR1XS
GI-1 MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG0c2ZKSzVyPUKuO|Yhdk1? MWHTRW5ITVJ?
HCC1806 NXjUVZM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXSdXpKSzVyPUKuPVEhdk1? M16y[HNCVkeHUh?=
HLE MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNibl2= MnjIV2FPT0WU
HSC-2 NFv2SmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP0TWM2OD1|LkCzJI5O MWDTRW5ITVJ?
DMS-273 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIm5O|lKSzVyPUOuNFchdk1? M{T4TnNCVkeHUh?=
DU-4475 NF3KSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G1WGlEPTB;Mz6xOEBvVQ>? MVXTRW5ITVJ?
LXF-289 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX6WIVyUUN3ME2zMlMyKG6P MVXTRW5ITVJ?
PANC-03-27 MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jsbGlEPTB;Mz61NUBvVQ>? NWe4PHNVW0GQR1XS
GAMG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHqS5dKSzVyPUOuO|Qhdk1? MYjTRW5ITVJ?
NCI-H522 M4HvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnZPFlvUUN3ME20MlM1KG6P MY\TRW5ITVJ?
SW626 NWfFfVlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L2RmlEPTB;ND60OkBvVQ>? NUPqTlgxW0GQR1XS
HT-144 NFTDTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTw[2hKSzVyPUSuPVIhdk1? MlPrV2FPT0WU
MEL-HO NI\nb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTnTWM2OD13LkG2JI5O NIHvSIZUSU6JRWK=
BE-13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF31XGpKSzVyPUWuNlEhdk1? NYnEVmlXW0GQR1XS
VA-ES-BJ MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTVwMk[gcm0> NFLKdm1USU6JRWK=
NCI-H441 NG\JXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDtPYlGUUN3ME21MlYhdk1? NIHiOFFUSU6JRWK=
KP-4 NETGeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXyTWM2OD13Lk[xJI5O MlvrV2FPT0WU
LoVo NUHTVGhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm3SGttUUN3ME21MlcyKG6P NVHMZlJbW0GQR1XS
HT-1080 Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PaPWlEPTB;NT64N{BvVQ>? NUnyVXdJW0GQR1XS
GB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTVwOESgcm0> Mo\YV2FPT0WU
IA-LM NI\G[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTVwOUGgcm0> MmnBV2FPT0WU
8-MG-BA MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTIOlhPUUN3ME21Mlk{KG6P NF\0OnFUSU6JRWK=
SK-HEP-1 NX24TlN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vPNGlEPTB;Nj6xOEBvVQ>? MWXTRW5ITVJ?
697 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD5cGV[UUN3ME22MlI2KG6P MV;TRW5ITVJ?
KYSE-450 M3;GNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37TOGlEPTB;Nj6zNkBvVQ>? NWrRd4F[W0GQR1XS
HCC2998 NWPPXmt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP1TnZKSzVyPU[uN|Qhdk1? M1v3fXNCVkeHUh?=
HD-MY-Z Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W4fWlEPTB;Nj62PEBvVQ>? MkDEV2FPT0WU
OS-RC-2 M3rlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrOO2JKSzVyPU[uOlghdk1? M{TYTHNCVkeHUh?=
SF126 M2XZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELWSJlKSzVyPUeuNFUhdk1? MVTTRW5ITVJ?
Ca-Ski MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC5TWM2OD15LkC5JI5O NYXMTZdWW0GQR1XS
NCI-H358 NHXRVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnZSFhEUUN3ME23MlE3KG6P M3j6S3NCVkeHUh?=
J82 NXz0TJFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jXOmlEPTB;Nz60NUBvVQ>? MofiV2FPT0WU
NCI-H2342 NV2ydpFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Lz[mlEPTB;Nz62N{BvVQ>? MWjTRW5ITVJ?
OVCAR-8 Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjucYJ4UUN3ME23Mlkhdk1? MXHTRW5ITVJ?
TE-8 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\Zb3plUUN3ME24JI5O NVzpbIN[W0GQR1XS
ETK-1 M13wemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnjd3hKSzVyPUiuNFghdk1? MVrTRW5ITVJ?
HAL-01 MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPDOlBKSzVyPUiuNkBvVQ>? NETVcGJUSU6JRWK=
KYSE-150 M{jXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRThwNEegcm0> M1rQd3NCVkeHUh?=
NCI-H810 NFnQW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;UPYlKSzVyPUiuOVYhdk1? MmG0V2FPT0WU
ONS-76 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRThwNkigcm0> MlXYV2FPT0WU
NMC-G1 NWjvSoQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXKdphTUUN3ME24Mlc3KG6P MVrTRW5ITVJ?
C3A MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LofmlEPTB;OD64OEBvVQ>? NIPTdGNUSU6JRWK=
PA-1 M3vZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojRTWM2OD16Lkm5JI5O NYjXZ|VSW0GQR1XS
SH-4 M1\NW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXWTWM2OD17LkCyJI5O NXHqZW5XW0GQR1XS
EFO-27 NG\kPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTlwMEWgcm0> NE\PNZBUSU6JRWK=
CAPAN-1 M1;pSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D6b2lEPTB;OT6yN{BvVQ>? NFzVUGhUSU6JRWK=
DU-145 NEjhbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjwdVRtUUN3ME25MlI6KG6P MWrTRW5ITVJ?
A101D MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ThPWlEPTB;OT6zO{BvVQ>? MXjTRW5ITVJ?
ST486 NYWxZ|lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX0TWM2OD17LkSxJI5O M1TvN3NCVkeHUh?=
NCI-H1437 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHzTHRVUUN3ME25MlQzKG6P M{fTVXNCVkeHUh?=
HGC-27 NEC2VZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq3TWM2OD17Lk[gcm0> MWPTRW5ITVJ?
8305C M1fId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfoN3RnUUN3ME25MlY1KG6P M2HEfnNCVkeHUh?=
OCUB-M MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFyLkCzJI5O MYfTRW5ITVJ?
COLO-679 M4\Hfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\6TWM2OD1zMD6wO{BvVQ>? M1nhR3NCVkeHUh?=
Detroit562 MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTTTWM2OD1zMD60NkBvVQ>? MVvTRW5ITVJ?
A204 M{fwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfUOXRKSzVyPUGxMlE3KG6P M4CzS3NCVkeHUh?=
NCI-H1734 M2G5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLvTWM2OD1zMT6yPUBvVQ>? M4TiU3NCVkeHUh?=
MC-CAR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LDUWlEPTB;MUGuOVghdk1? MnfqV2FPT0WU
NCI-H2170 NXqwXFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:1TWM2OD1zMT65O{BvVQ>? MoL6V2FPT0WU
NCI-SNU-5 NEHzcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTGUpoxUUN3ME2xNk4yOyCwTR?= M1XuUHNCVkeHUh?=
HCE-T MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjSTWM2OD1zMj60NkBvVQ>? NGDnb4xUSU6JRWK=
KYSE-180 NVLjcXh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLSTWM2OD1zMj64NUBvVQ>? MWfTRW5ITVJ?
C8166 NGH3d5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfYcFNKSzVyPUGzMlA5KG6P Ml7SV2FPT0WU
NCI-H460 NEPxO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XLUmlEPTB;MUOuOVQhdk1? NUXPSmZPW0GQR1XS
SNU-449 M3LDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKxTZJKSzVyPUGzMlc4KG6P NEe1[GVUSU6JRWK=
MDA-MB-468 NWLjUYtWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF2LkGyJI5O Mkj4V2FPT0WU
COR-L23 MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDjVJRGUUN3ME2xOE4yOyCwTR?= NG\QTVlUSU6JRWK=
CTV-1 NHnVOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnxcodRUUN3ME2xOE4yPCCwTR?= NYT5RZFrW0GQR1XS
BL-41 M4niUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPncnVOUUN3ME2xOE4{PyCwTR?= M1\henNCVkeHUh?=
IGR-1 NET6Z3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLsVpVKSzVyPUG0MlQzKG6P MWPTRW5ITVJ?
TK10 M{jHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PqTGlEPTB;MUSuOFkhdk1? NVWyb4RpW0GQR1XS
REH NYXJV|VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\MTWM2OD1zND61NUBvVQ>? MYTTRW5ITVJ?
LU-139 MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfMVnpsUUN3ME2xOE42QSCwTR?= M4XLfHNCVkeHUh?=
KP-N-YS NIPr[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fa[2lEPTB;MUSuPVchdk1? NGnZSWZUSU6JRWK=
PANC-10-05 M37lOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF3LkO4JI5O Ml7HV2FPT0WU
HL-60 M3fWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;1flJpUUN3ME2xOU43QSCwTR?= NWDYfpJXW0GQR1XS
T84 NWW3SItFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV33TXhsUUN3ME2xOU46PiCwTR?= M3K5WXNCVkeHUh?=
RPMI-8226 NILC[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF4LkCyJI5O NYnUfZViW0GQR1XS
UM-UC-3 NVTiUmJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\4TWM2OD1zNj6xOkBvVQ>? MVfTRW5ITVJ?
TE-10 NWe1WFVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF4LkKxJI5O MUDTRW5ITVJ?
CAL-148 M4HqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHPTWM2OD1zNz6yN{BvVQ>? NHu3VXpUSU6JRWK=
BV-173 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF5LkK3JI5O Mo\lV2FPT0WU
Calu-3 M4\Ie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rvNWlEPTB;MUeuNlkhdk1? MmfmV2FPT0WU
RPMI-2650 NGfZW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF5LkW5JI5O MXXTRW5ITVJ?
MKN45 M4Th[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF5LkezJI5O Mm\4V2FPT0WU
NUGC-3 NELtUI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHGTWM2OD1zOD6zOEBvVQ>? MV3TRW5ITVJ?
NCI-H520 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7ybGJKSzVyPUG4Mlc4KG6P MkPUV2FPT0WU
CCRF-CEM MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF6Lki1JI5O MWHTRW5ITVJ?
NCI-H2405 M1TRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXWUIVWUUN3ME2xPU4yKG6P M1fBS3NCVkeHUh?=
ES7 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rveWlEPTB;MUmuO|Yhdk1? Mn3EV2FPT0WU
BPH-1 NYexdnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzp[mpKSzVyPUKwMlI5KG6P NF\LSYlUSU6JRWK=
SAS MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7xfYVKSzVyPUKwMlUhdk1? NWK1NG5ZW0GQR1XS
HuCCT1 NIrtTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV60dIt4UUN3ME2yNE42QCCwTR?= NIj1XIFUSU6JRWK=
LOUCY NYDYWJBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHw[5VLUUN3ME2yNE43PiCwTR?= NGnleZVUSU6JRWK=
NCI-H292 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:zR4tKSzVyPUKwMlc6KG6P NWnMTHdPW0GQR1XS
G-361 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rHZ2lEPTB;MkGuNFchdk1? MkfKV2FPT0WU
M059J NGfHVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm5TWM2OD1{MT6wPEBvVQ>? M{LNe3NCVkeHUh?=
NCI-H1651 NXv3W2ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HQd2lEPTB;MkGuNVEhdk1? NFW4fYpUSU6JRWK=
KALS-1 NG\MT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJzLkO5JI5O NILnUZNUSU6JRWK=
DJM-1 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJzLkW5JI5O MlXoV2FPT0WU
AU565 M1:1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrsfmVKSzVyPUKxMlg{KG6P MXnTRW5ITVJ?
HCC38 NFnRZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELNOWpKSzVyPUKxMlk2KG6P MnXXV2FPT0WU
U251 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXWeIdKSzVyPUKyMlI4KG6P NXLscWNkW0GQR1XS
ABC-1 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K1OGlEPTB;MkKuOlUhdk1? M3fP[nNCVkeHUh?=
SK-NEP-1 NXGycI1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;F[YFLUUN3ME2yNk46OyCwTR?= NHi3OYFUSU6JRWK=
CESS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq3Z4g5UUN3ME2yN{4yQSCwTR?= NXvofVRJW0GQR1XS
MIA-PaCa-2 NHv0WpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fhOWlEPTB;MkOuN|Yhdk1? MonLV2FPT0WU
SUP-T1 M4XO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJ|LkS3JI5O MVrTRW5ITVJ?
L-428 M{TTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MormTWM2OD1{Mz62NkBvVQ>? NX3Fd2xmW0GQR1XS
SW954 NYPtWpIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TOVWlEPTB;MkOuOlghdk1? NXq3W4tTW0GQR1XS
HO-1-N-1 M3q3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH1N41qUUN3ME2yN{44PyCwTR?= NYfXcpM1W0GQR1XS
CHP-126 NVnK[nZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDtW2tKSzVyPUK0MlE1KG6P NGXrb3pUSU6JRWK=
HMV-II NYnPfIprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXKV3FKSzVyPUK0MlM1KG6P NYCxXJdwW0GQR1XS
NB10 M2PRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnKXWt3UUN3ME2yOE4{PyCwTR?= NFnq[XJUSU6JRWK=
A172 NX[0dm4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO5TWM2OD1{ND63NUBvVQ>? MW\TRW5ITVJ?
MONO-MAC-6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ2Lki0JI5O NVmySoxOW0GQR1XS
NCI-H1650 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PIZWlEPTB;MkWuOEBvVQ>? MnHwV2FPT0WU
NH-12 M4j2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJ3LkWgcm0> M2HjfXNCVkeHUh?=
ML-2 NULqdY96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\rO2lEPTB;MkWuO|Qhdk1? MkHRV2FPT0WU
MZ2-MEL MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\rTWM2OD1{Nj6yNkBvVQ>? MWjTRW5ITVJ?
COLO-684 NEjwZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDKTWM2OD1{Nj60NUBvVQ>? M3\5fXNCVkeHUh?=
HuP-T4 MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e1VWlEPTB;MkeuN{BvVQ>? MVnTRW5ITVJ?
SW837 NGrZXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXrRXpKSzVyPUK3MlYzKG6P NUTxV2xqW0GQR1XS
MDA-MB-231 NF\vOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXTTWM2OD1{Nz63PEBvVQ>? MnXBV2FPT0WU
KYSE-140 M{ThW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP3ZpFKSzVyPUK3MlkyKG6P NViw[phiW0GQR1XS
NOMO-1 NF;UWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnQbG9KSzVyPUK4MlY5KG6P M1XNT3NCVkeHUh?=
GP5d MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHCTWM2OD1{OD63NkBvVQ>? NYr5TFVCW0GQR1XS
COR-L105 NFu5T2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ7LkSyJI5O NH3nS41USU6JRWK=
LS-411N M37jPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16zfGlEPTB;MkmuPFghdk1? MlHlV2FPT0WU
NY MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\lS4hKSzVyPUOwMlE5KG6P MkXCV2FPT0WU
NCI-H2030 Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTNyLkS1JI5O Mk\tV2FPT0WU
CCF-STTG1 MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTNzLkSyJI5O MoPBV2FPT0WU
NCI-H1703 NUn3PXkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTNzLke4JI5O MWLTRW5ITVJ?
TUR M2e3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rVR2lEPTB;M{KuNFMhdk1? M3v5TXNCVkeHUh?=
NOS-1 NEn0[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTN{LkS0JI5O MVTTRW5ITVJ?
A2058 M4[wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TjcGlEPTB;M{KuPFMhdk1? NULodGo6W0GQR1XS
LCLC-103H M4LJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTN|LkK1JI5O MVfTRW5ITVJ?
NCI-H510A MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTN|LkK3JI5O NFf2WnZUSU6JRWK=
BC-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rtTGlEPTB;M{OuO|chdk1? MkDkV2FPT0WU
SK-CO-1 NVTmS4tGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j1VmlEPTB;M{SuNFEhdk1? MlzvV2FPT0WU
A673 NXP4WHRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPYTWM2OD1|ND6xO{BvVQ>? NVHldVN4W0GQR1XS
VM-CUB-1 M4C2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTFe4Z7UUN3ME2zOE43QSCwTR?= MkXOV2FPT0WU
HH M1XESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN3LkC2JI5O NGHJOGlUSU6JRWK=
CAL-27 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rJWWlEPTB;M{WuNVYhdk1? NYDSOplXW0GQR1XS
NEC8 NW\QWYJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN3LkO3JI5O MWDTRW5ITVJ?
BxPC-3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVradW1iUUN3ME2zOk46OSCwTR?= MYfTRW5ITVJ?
SNB75 NV7qRnpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NISyRVVKSzVyPUO3MlI1KG6P M4S0T3NCVkeHUh?=
NB13 NYDpc|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvBSYNYUUN3ME2zPE4zOyCwTR?= NI\LOWVUSU6JRWK=
SK-OV-3 NYXpZVMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu3So5KSzVyPUO4Mlc1KG6P MWjTRW5ITVJ?
ME-180 M2PDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXnTWM2OD1|OD64JI5O M3jR[3NCVkeHUh?=
JiyoyeP-2003 NFrtRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD4T5hNUUN3ME2zPU4{QCCwTR?= M17QNXNCVkeHUh?=
LU-134-A MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLVTWM2OD12MD6wNkBvVQ>? NVPXcWJSW0GQR1XS
LS-123 M1L6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\aTWM2OD12MD6yPEBvVQ>? M132OXNCVkeHUh?=
COLO-800 NGK4dmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK1[W1KSzVyPUSwMlU3KG6P MlPRV2FPT0WU
LB831-BLC M3vYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTRzLki1JI5O NWPZcHliW0GQR1XS
NCI-H747 NH;IfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR{LkK4JI5O NHvNbYFUSU6JRWK=
MZ7-mel NW\yU25zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTR{Lk[2JI5O M3XqT3NCVkeHUh?=
GT3TKB NWPjUZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f0N2lEPTB;NEKuO|Ihdk1? NXLMeGdEW0GQR1XS
MOLT-16 M2X3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkflTWM2OD12Mz6wOUBvVQ>? M2PmVHNCVkeHUh?=
23132-87 NFLGO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTR|LkC1JI5O NIfnfWJUSU6JRWK=
PF-382 M17zSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR2LkKyJI5O MYjTRW5ITVJ?
ES3 NYPodGh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHKTWM2OD12ND62JI5O M4DQSXNCVkeHUh?=
SW756 NWLqRWMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTR3LkG0JI5O NXS1VG1CW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p70S6K1 / p-S6 / HIF-1α ; 

PubMed: 27765914     


Cells were treated with different doses of gemcitabine (0, 1.5 and 2.5 μM), the expression levels of p70S6K1, p-S6 and HIF-1α were determined by Western blotting. GAPDH is used as an internal control.

PARP / Cleaved PARP / Cleaved caspase-3 / phopho-p38 / p38 / p-JNK / JNK / p-c-Jun; 

PubMed: 24409315     


AsPC-1, BxPC-3, and COLO-357 cells were incubated for the indicated times with 100 ng/ml, 10 ng/ml, and 5 ng/ml gemcitabine, respectively, and analyzed by immunoblotting. 

27765914 24409315
Immunofluorescence
Bim1; 

PubMed: 27177084     


Gemcitabine enhanced nuclear accumulation of Bmi1 by immunofluorescence staining. The graphs shown are representative results of three independently repeated experiments. Scale bar, 50 μm.

27177084
Growth inhibition assay
Cell viability; 

PubMed: 27765914     


A and B. Pancreatic adenocarcinoma cells Bxpc-3 (A) and Panc-1 (B) were treated with gemcitabine (GEM) for 48 h at different doses. The cell viability was analyzed by CCK-8 assay, and normalized to cells without gemcitabine treatment. 

27765914
In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04051047 Not yet recruiting Drug: Gemcitabine|Procedure: Tumor biopsy and blood draw Glial Tumor of Brain|Diffuse Intrinsic Pontine Glioma|Glioma University of Michigan Rogel Cancer Center|University of Colorado Denver November 30 2019 Early Phase 1
NCT03669601 Not yet recruiting Drug: AZD6738|Drug: Gemcitabine Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust September 30 2019 Phase 1
NCT04046887 Not yet recruiting Drug: Lonsurf|Drug: Gemcitabine|Drug: Nab-Paclitaxel Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma Patrick Joseph Loehrer Sr.|Indiana University|Taiho Oncology Inc. August 2019 Phase 1
NCT03865563 Not yet recruiting Drug: Retrograde venous infusion of gemcitabine/lipiodol Pancreatic Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID